Nursing News and Research

Latest Nursing News and Research

Short Jump training program may help lower risk of knee injuries in women basketball players: Study

A shortened, focused "jump training" program may help to lower the risk of knee injuries in women basketball players, according to a study in the December issue of The Journal of Strength and Conditioning Research, official research journal of the National Strength and Conditioning Association.

8 Dec 2010

Loss of healthy bacteria may contribute to increasing rates of depression, say researchers

In an effort to pinpoint potential triggers leading to inflammatory responses that eventually contribute to depression, researchers are taking a close look at the immune system of people living in today's cleaner modern society.

8 Dec 2010

UC researchers launch clinical trial to study post-stroke brain injury

The largest clinical trial of therapeutic brain cooling after stroke has launched, led by researchers at the University of California, San Diego, the University of Texas Health Science Center at Houston, and at Cedars-Sinai Medical Center in Los Angeles. This study looks at whether hypothermia can safely be used in elderly stroke patients.

8 Dec 2010

Jackson Health System selects MedAssets as its strategic partner

MedAssets, Inc. announced today that Jackson Health System has selected the Company as its strategic partner to implement MedAssets' transformational approach to significantly lower supply costs, drive operational efficiencies and engage physicians in the cost and clinical utilization management improvement process.

8 Dec 2010

Proactive therapies may prove to avert stroke in patients with atrial fibrillation

One evening last March, Larry Ambrose left his bed in the middle of the night to check the time. Much to the 71-year-old's surprise, he was only able to see three out of the four glowing numbers on the digital clock in his kitchen. Ambrose returned to bed, but within days was hospitalized for what was later diagnosed as a stroke. After extensive testing, his physicians told him they could not determine the cause.

8 Dec 2010

Lutheran Medical Center implements Medsphere's OpenVista EHR solution

Lutheran Medical Center (LMC) and Medsphere Systems Corporation today announced the successful implementation of Medsphere's OpenVista® electronic health record (EHR) solution throughout the hospital. The full service 476-bed teaching hospital is now on track to achieve meaningful use and qualify for millions of dollars made available by the American Recovery and Reinvestment Act of 2009.

7 Dec 2010

John Theurer Cancer Center presents research findings at ASH meeting

The John Theurer Cancer Center at Hackensack University Medical Center announced today important research findings presented at the annual meeting of the American Society of Hematology taking place December 4-7, 2010 in Orlando, Florida. The ASH meeting is the world's leading scientific gathering of hematologists and hematology researchers.

7 Dec 2010

Data from comparative REVLIMID study in multiple myeloma presented at 52nd ASH

Celgene International Sàrl today announced that data from a randomised clinical study conducted by the Eastern Cooperative Oncology Group (ECOG) were presented at the 52nd Annual Meeting of the American Society of Hematology comparing REVLIMID® (lenalidomide) plus low-dose dexamethasone (Rd) to lenalidomide plus high-dose dexamethasone (RD) in both younger and older newly-diagnosed multiple myeloma patients (NDMM).

7 Dec 2010

Breast cancer patients taking tamoxifen anxious to have CYP2D6 genetic test

While the medical community continues to debate the benefits of CYP2D6 genetic testing for women on the breast cancer treatment tamoxifen, patients using the medication are anxious to have the tests. According to a new survey of more than 700 women with breast cancer currently taking tamoxifen, almost 80 percent of respondents would choose to have a genetic test that determines CYP2D6 genotype, yet only 14 percent of these women have been tested. CYP2D6 is an enzyme that influences how well the body processes tamoxifen into its more active form.

7 Dec 2010

FDA accepts for review Bristol-Myers Squibb's ORENCIA sBLA for severe RA

Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental Biologics License Application (sBLA) for the subcutaneous formulation of ORENCIA® (abatacept), a treatment for adult patients with moderate to severe rheumatoid arthritis (RA) administered through an injection into the skin. Bristol-Myers Squibb submitted the sBLA to the FDA for the subcutaneous formulation of ORENCIA and received confirmation of its receipt on October 4, 2010.

7 Dec 2010

Today's Op-Eds: ObamaCare and FEHBP; California prisons; and workhorse Medicaid

Even Washington's stupidest scandals can be revealing, and so it is with the liberal cri de snore that Republicans ought to renounce health insurance. Democrats have inadvertently drawn up another indictment of ObamaCare (12/4).

6 Dec 2010

$Allos Therapeutics reports new analysis of PROPEL trial data of FOLOTYN in patients with refractory PTCL$

Allos Therapeutics reports new analysis of PROPEL trial data of FOLOTYN in patients with refractory PTCL

Allos Therapeutics, Inc. today reported new analysis of data from the Company's pivotal PROPEL trial of FOLOTYN (pralatrexate injection) in patients with relapsed or refractory peripheral T-cell lymphoma at the 52nd American Society of Hematology Annual Meeting in Orlando, Florida.

6 Dec 2010

Elsevier announces title change for Cancer Genetics and Cytogenetics journal

Elsevier, the world's leading publisher of scientific, technical and medical information, announced today that its highly respected Cancer Genetics and Cytogenetics journal is changing its title to Cancer Genetics and has named Dr. Jaclyn A. Biegel as editor-in-chief.

6 Dec 2010

Researchers show link between accepting family attitudes, behaviors towards LGBT children

For the first time, researchers have established a clear link between accepting family attitudes and behaviors towards their lesbian, gay, bisexual and transgender children and significantly decreased risk and better overall health in adulthood.

6 Dec 2010

$Updated Phase 1 study results of FOLOTYN in patients with refractory CTCL presented at ASH 2010$

Updated Phase 1 study results of FOLOTYN in patients with refractory CTCL presented at ASH 2010

Allos Therapeutics, Inc. today reported updated results from the Company's Phase 1 dose-finding study of FOLOTYN® (pralatrexate injection) which supports the selection of 15 mg/m2 weekly for three weeks out of a four-week cycle as the optimal starting dose and schedule for further evaluation in patients with relapsed or refractory cutaneous T-cell lymphoma. Data were presented at the 52nd American Society of Hematology Annual Meeting in Orlando, Florida.

6 Dec 2010

Study: REVLIMID and dexamethasone for high-risk smoldering multiple myeloma reduce risk of disease progression

Celgene International Sàrl (NASDAQ: CELG) announced that data evaluating combination therapy REVLIMID® (lenalidomide) and dexamethasone in patients with high-risk asymptomatic smoldering multiple myeloma were presented during the American Society of Hematology's annual meeting. The study reported REVLIMID and dexamethasone prolonged time to progression.

6 Dec 2010

Texas gov. Perry backs away from Medicaid dropout threat

Medicaid and the Children's Health Insurance Program are breaking the state's budget, but opting out of the federal programs would have a devastating effect on health care delivery in Texas, according to a state report issued Friday. The report said most of the methods for fixing Medicaid spending in Texas will require acts of Congress, not the Legislature, to give the state greater flexibility in how the programs are run and a greater share of the national Medicaid financing.

6 Dec 2010

Investigational study data of REVLIMID with rituximab or rituximab-containing regimen in CLL patients presented at ASH

Celgene International Sàrl announced that clinical data from two investigational studies evaluating the use of REVLIMID (lenalidomide) either with rituximab or following a rituximab-containing regimen in patients with chronic lymphocytic leukaemia were presented at the 52nd American Society of Hematology annual meeting.

6 Dec 2010

$Pivotal PROPEL trial data of FOLOTYN in patients with refractory PTCL reported at ASH Annual Meeting$

Pivotal PROPEL trial data of FOLOTYN in patients with refractory PTCL reported at ASH Annual Meeting

Allos Therapeutics, Inc. today reported new analyses of data from the Company's pivotal PROPEL trial of FOLOTYN (pralatrexate injection) in patients with relapsed or refractory peripheral T-cell lymphoma at the 52nd American Society of Hematology Annual Meeting held in Orlando, Florida.

6 Dec 2010

Researchers adapt gene chip microarray technology to study glycans

Sugar molecules coat every cell in our bodies and play critical roles in development and disease, yet the components of these "glycans" have been difficult for scientists to study, because of their complexity.

6 Dec 2010

Nursing News and Research

Latest Nursing News and Research

Short Jump training program may help lower risk of knee injuries in women basketball players: Study

Loss of healthy bacteria may contribute to increasing rates of depression, say researchers

UC researchers launch clinical trial to study post-stroke brain injury

Jackson Health System selects MedAssets as its strategic partner

Proactive therapies may prove to avert stroke in patients with atrial fibrillation

Lutheran Medical Center implements Medsphere's OpenVista EHR solution

John Theurer Cancer Center presents research findings at ASH meeting

Data from comparative REVLIMID study in multiple myeloma presented at 52nd ASH

Breast cancer patients taking tamoxifen anxious to have CYP2D6 genetic test

FDA accepts for review Bristol-Myers Squibb's ORENCIA sBLA for severe RA

Today's Op-Eds: ObamaCare and FEHBP; California prisons; and workhorse Medicaid

Allos Therapeutics reports new analysis of PROPEL trial data of FOLOTYN in patients with refractory PTCL

Elsevier announces title change for Cancer Genetics and Cytogenetics journal

Researchers show link between accepting family attitudes, behaviors towards LGBT children

Updated Phase 1 study results of FOLOTYN in patients with refractory CTCL presented at ASH 2010

Study: REVLIMID and dexamethasone for high-risk smoldering multiple myeloma reduce risk of disease progression

Texas gov. Perry backs away from Medicaid dropout threat

Investigational study data of REVLIMID with rituximab or rituximab-containing regimen in CLL patients presented at ASH

Pivotal PROPEL trial data of FOLOTYN in patients with refractory PTCL reported at ASH Annual Meeting

Researchers adapt gene chip microarray technology to study glycans

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Nursing News and Research

Latest Nursing News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in